We are dedicated to developing the next generation of targeted drugs for treatment of human cancer.
Curis is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. Curis is building upon its previous experiences, including targeting the Hedgehog pathway by the approved drug, Erivedge®, to further the advancement of its proprietary pipeline of targeted cancer programs. Learn more »